PGI Is Contemplating To Start In-House Testing Of Medicines

CHANDIGARH : After the recent cases of drug contamination and adverse events at PGI, the institute is contemplating to start in-house testing of medicines, a facility lacking in any public hospital in the country.

There are regional and central drugs laboratories and some private centres which are approved by the DCGI to test and analyse suspected medicine samples. No hospital has the large scale facility or infrastructure for testing medicine safety and efficacy.

“We are actively working on it. It should be operational sooner than later. It will be a double check. We will not have to depend on outside resources,” said Prof Vivek Lal, director, PGI.

After five deaths of patients who were to be operated upon and were administered sedative drug Propofol, the PGI had sent the samples of the medicine to the drug control authorities in the city. It took almost a month for the test analysis report. With the in-house testing, the hospital will be able to conclude with evidence if the adverse event was due to the medicines or other complications.

“The sample was also tested by the pharmacology department in the PGI and in Panjab University. But in the absence of the requisite infrastructure/reagents, the test was not as validated as from the approved government testing laboratories,” said a faculty member at PGI.

The laboratory will follow pharmacopoeia monographs — documents which are taken as reference for testing of drugs — and had to be good manufacturing practice compliant. “When the facility is ready, suspected drugs will be tested here prior to giving it to the patients who are admitted for surgery or for treatment. However, for any legal action, the samples will also be sent to the approved government laboratories,” said a senior faculty member.

  • Related Posts

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?